HDAX Therapeutics is pioneering a next-generation approach to drug design through its proprietary technology that focuses on the targeting of HDAC6, a protein involved in various biological functions such as cellular transport and immunomodulation. This innovative technology employs a unique 2-site binding mechanism that enhances the efficacy, selectivity, and safety profile of small molecules aimed at treating diseases with inadequate current therapies. By leveraging over seven years of foundational research, HDAX aims to address critical drug-design challenges and unlock the therapeutic potential of HDAC6 across a range of conditions, including neurological and cardiometabolic diseases.

The company's approach is characterized by its ability to reverse disease phenotypes linked to aberrant HDAC6 activity, utilizing advanced techniques such as rational drug design, X-ray crystallography, and computer-aided drug discovery. This enables HDAX to create highly potent treatments that can operate effectively at low concentrations and have a prolonged duration of action. The versatility of HDAC6 as a therapeutic target allows for potential applications in various diseases, including peripheral neuropathies and chronic heart failure, positioning HDAX Therapeutics as a leader in developing transformative medicines that could significantly improve patient outcomes.

Canada

Pioneering next-gen precision therapeutics for diseases stemming from microtubule dysfunction, such as neuropathies and cardiovascular diseases.

HDAX Therapeutics

Company Details